Abstract
Over the last decade, the use of tumor necrosis factor (TNF) inhibitors has improved the prognosis of patients with rheumatoid arthritis. Although these agents are more efficacious than traditional DMARDs, a substantial proportion of patients discontinue anti-TNF therapy because of adverse effects or lack of efficacy. Therapeutic options for these patients include dose increases, switching to an alternative TNF antagonist, or switching to a biologic of a different class, such as rituximab or abatacept. The recently published results of the RADIATE study by Emery et al. suggest that the interleukin-6 inhibitor tocilizumab is a safe and effective alternative for patients who fail to respond to anti-TNF therapy. Randomized controlled trials and the study of biomarkers are needed to help clinicians select the most suitable of these options for their patients.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures
Arthritis Research & Therapy Open Access 23 February 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hyrich KL et al. (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56: 13–20
Smolen JS et al. (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371: 987–997
Genovese MC et al. (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58: 2968–2980
Emery P et al. (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67: 1516–1523
Nishimoto N et al. (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66: 1162–1167
Finckh A et al. (2007) B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56: 1417–1423
Smolen J et al. (2008) Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): results of the randomized, double-blind, placebo-control trial [abstract #OP-0010]. Ann Rheum Dis 67 (Suppl 2): 50
Cohen SB et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54: 2793–2806
Genovese MC et al. (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353: 1114–1123
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has received speakers' honoraria and grants/research support from and has been a consultant for Abbott Immunology, Roche, Schering–Plough, UCB Pharma and Wyeth.
Rights and permissions
About this article
Cite this article
Choy, E. RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists. Nat Rev Rheumatol 5, 66–67 (2009). https://doi.org/10.1038/ncprheum0984
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0984
This article is cited by
-
Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis
Basic Research in Cardiology (2014)
-
Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures
Arthritis Research & Therapy (2011)